Xalkori (crizotinib capsules and oral pellets) — Cigna
Anaplastic Large Cell Lymphoma (ALK-positive, relapsed/refractory or palliative-intent)
Initial criteria
- Patient age ≥ 1 year
- Patient has anaplastic lymphoma kinase (ALK)-positive disease
- Medication is used for palliative-intent therapy OR patient has relapsed or refractory disease
Approval duration
1 year